We are monitoring the impact of COVID-19 on MEA Therapeutic Vaccines Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 62
Share on
Share on

Middle-East and Africa Therapeutic Vaccines Market Research Report – Segmented By Disease Type and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 62
Pages: 136

MEA Therapeutic Vaccines Market Size (2021 to 2026)

The size of the Therapeutic Vaccines Market in MEA was calculated at USD 314.95 Million in 2021. It is forecasted to grow USD 1504.00 Million by 2026, growing at a CAGR of 36.71% from 2021 to 2026.

Therapeutic vaccinations have grown in popularity as the prevalence of illnesses like cancer and HIV has increased. Technological advancements in HIV detection and expanded clinical trials for HIV and cancer vaccines are two important drivers driving the growth of the MEA therapeutic vaccines market. Furthermore, greater public awareness of critical illnesses and increased R&D spending on therapeutic vaccines boost the market for therapeutic vaccines.

Increased government funding for vaccine development, increased investments by leading market players, growing disease incidence, technical improvements, and NGOs' activities are some of the reasons driving the market forward.

The MEA market for therapeutic vaccines has been greatly influenced by the increasing prevalence of different chronic illnesses such as cancer, HIV, and cardiovascular disorders. Although these developments are still in the works and have yet to be commercialized, they suggest a new market potential for MEA therapeutic vaccines. In addition, malignancies caused by the human papillomavirus provide a potential opportunity for the MEA therapeutic vaccines market. 

Massive capital expenditures, strict regulatory restrictions, and expensive treatment costs are a few reasons limiting the market's growth. Higher vaccination prices and a lack of therapeutic medication availability are limiting the MEA therapeutic vaccines industry. Furthermore, tight regulatory criteria for therapeutic vaccine approval impeded the MEA global therapeutic vaccines market. Ineffective research and development policies, as well as reimbursement regulations, are limiting the market.

The rise of the MEA therapeutic vaccines industry may be threatened by adverse side effects of therapeutic vaccination and a lack of understanding. In addition, issues such as the expensive cost of producing therapeutic vaccines will stifle market expansion.

Vaccine research and development, like medicine development, takes a long time and a lot of money. Before a vaccine can be commercially released, clinical trials must be completed. Unfortunately, many vaccines fail to succeed during these trials.

This research report on the Middle-East & Africa therapeutic vaccines market has been segmented and sub-segmented into the following categories:

By Disease Type: 

  • Autoimmune Disease
  • Cancer
  • Neurological Disease
  • Infectious Disease

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Several governments and humanitarian groups have taken initiatives to prevent diseases and vaccinate as many children and adults as possible, which led to a change in production and supply strategies and a rise in the donor market, the biggest market for vaccines.

Following the Middle East, Africa has the largest market share for MEA therapeutic vaccines. Africa has a significant HIV/AIDS epidemic, as well as a high AIDS rate. Despite having just 15.2 percent of the world's population, Africa accounts for over 70% of all AIDS-related fatalities and 69% of all HIV-related deaths. In South Africa, a clinical experiment for Aids therapy has yielded promising findings. HIV patients with the HIV vaccine have a more robust immune system, making antiviral drugs more effective. With an AIDS-infected population in the African subcontinent, this probably indicates an increase in therapeutic vaccines. This, coupled with the Middle East economies' spending power and their recently booming markets, makes this region a lucrative one for market players.

KEY MARKET PLAYERS:

Some of the prominent companies leading the Middle-East & Africa Therapeutic Vaccines Market profiled in the report are GlaxoSmithKline, plc, Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Analysis Design                         

                2.3 Research Phases                      

                                2.3.1 Secondary Research            

                                2.3.2 Primary Research 

                                2.3.3 Econometric Modelling     

                                2.3.4 Expert Validation  

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Disease Type                       

                                5.1.1 Autoimmune Disease Vaccines      

                                5.1.2 Cancer Vaccines   

                                                5.1.2.1 Multikine

                                                5.1.2.2 PR1 Peptide

                                                5.1.2.3 TroVax

                                                5.1.2.4 CYT004-MelQbG10

                                5.1.3 Neurological Disease Vaccines        

                                                5.1.3.1 ACC- 001

                                                5.1.3.2 CAD 106

                                                5.1.3.3 Parkinson's Disease Vaccine

                                                5.1.3.4 Alzheimer's Disease

                                5.1.4 Infectious Disease Vaccines             

                                                5.1.4.1 Hepatitis C

                                                5.1.4.2 HIV/AIDS

                                                5.1.4.3 Other Infectious Disease

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 Middle East                

                6.3 Africa                            

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 GlaxoSMithKline plc.                              

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Strategic Evaluation and Operations            

                                8.1.4 Financial analysis  

                                8.1.5 Legal issues            

                                8.1.6 Recent Developments       

                                8.1.7 SWOT analysis       

                                8.1.8 Analyst View          

                8.2 Merck and Company                              

                8.3 Bavarian Nordic                        

                8.4 CSL Limited                 

                8.5 Emergent Biosolutions Inc.                  

                8.6 Novartis AG                

                8.7 Johnson and Johnson                             

                8.8 MedImmune LLC                     

                8.9 Pfizer Inc.                    

                8.10 Sanofi Pasteur                        

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Expert Opinions                                         

                10.1 Market Outlook                     

                10.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and identify the regions that are still untapped.
  • The segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions to provide both individuals and organizations a strong financial foothold in the market, investment opportunities Expertly devised analyst overview along with
  1. Middle East & Africa Therapeutic Vaccines Market, By Region, From 2021 to 2026 (USD Million)
  2. Middle East & Africa Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Million)
  3. Middle East & Africa Autoimmune Disease Vaccines Market, By Region, From 2021 to 2026 (USD Million)
  4. Middle East & Africa Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Million)
  5. Middle East & Africa Neurological Disease Vaccines Market, By Region, From 2021 to 2026 (USD Million)
  6. Middle East & Africa Infectious Disease Vaccines Market, By Region, From 2021 to 2026 (USD Million)
  7. Middle East & Africa Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Million)
  8. Middle East & Africa Multikine Market, By Region, From 2021 to 2026 (USD Million)
  9. Middle East & Africa PR1 Peptide Market, By Region, From 2021 to 2026 (USD Million)
  10. Middle East & Africa TroVax Market, By Region, From 2021 to 2026 (USD Million)
  11. Middle East & Africa CYT004-MelQbG10 Market, By Region, From 2021 to 2026 (USD Million)
  12. Middle East & Africa Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Million)
  13. Middle East & Africa ACC- 001 Market, By Region, From 2021 to 2026 (USD Million)
  14. Middle East & Africa CAD 106 Market, By Region, From 2021 to 2026 (USD Million)
  15. Middle East & Africa Parkinson's Vaccine Market, By Region, From 2021 to 2026 (USD Million)
  16. Middle East & Africa Alzheimer's Vaccine Market, By Region, From 2021 to 2026 (USD Million)
  17. Middle East & Africa Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Million)
  18. Middle East & Africa Hepatitis C Vaccines Market, By Region, From 2021 to 2026 (USD Million)
  19. Middle East & Africa HIV/AIDS Vaccines Market, By Region, From 2021 to 2026 (USD Million)
  20. Middle East & Africa Other Infectious Disease Vaccines Market, By Region, From 2021 to 2026 (USD Million)
  21. Middle East Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Million)
  22. Africa Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Million)
  23. Middle East Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Million)
  24. Africa Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Million)
  25. Middle East Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Million)
  26. Africa Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Million)
  27. Middle East Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Million)
  28. Africa Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample